PMID- 32174196
OWN - NLM
STAT- MEDLINE
DCOM- 20210121
LR  - 20210121
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 19
IP  - 5
DP  - 2020 May
TI  - The safety of baricitinib in patients with rheumatoid arthritis.
PG  - 545-551
LID - 10.1080/14740338.2020.1743263 [doi]
AB  - Introduction: Despite improvement in disease outcomes and prognosis, a 
      substantial number of patients with rheumatoid arthritis (RA) still require a 
      novel agent for effective treatment. Baricitinib is a targeted synthetic 
      disease-modifying antirheumatic drug (tsDMARDs) that selectively inhibits Janus 
      kinase (JAK1/JAK2), an important enzyme in the pathogenesis of RA.Areas covered: 
      This paper aimed to evaluate the pharmacodynamics and pharmacokinetics of 
      baricitinib while reviewing its safety and efficacy in the treatment of RA.Expert 
      opinion: Randomized controlled trials of baricitinib showed its efficacy and 
      safety in patients with active RA who were methotrexate (MTX)-naive or were not 
      adequately responsive to MTX, conventional synthetic DMARDs, or tumor necrosis 
      factor inhibitors. Baricitinib may be suitable in patients who prefer oral 
      therapy and do not have a history of severe renal impairment, recent history of 
      malignancy, or risk factors for adverse events (AEs) such as venous 
      thromboembolism, opportunistic infection, and diverticulitis. Dose adjustment of 
      baricitinib, based on the assessment of patient conditions including their renal 
      function and disease activity, is an important strategy for successful and safe 
      treatment. However, long-term post-marketing surveillance studies with a larger 
      sample size are required to evaluate the overall safety and AEs with low 
      incidence rates in clinical settings.
FAU - Honda, Suguru
AU  - Honda S
AUID- ORCID: 0000-0003-4846-3234
AD  - Department of Rheumatology, School of Medicine, Tokyo Women's Medical University, 
      Tokyo, Japan.
FAU - Harigai, Masayoshi
AU  - Harigai M
AUID- ORCID: 0000-0002-6418-2603
AD  - Department of Rheumatology, School of Medicine, Tokyo Women's Medical University, 
      Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200321
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Azetidines)
RN  - 0 (Purines)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - EC 2.7.10.2 (JAK1 protein, human)
RN  - EC 2.7.10.2 (JAK2 protein, human)
RN  - EC 2.7.10.2 (Janus Kinase 1)
RN  - EC 2.7.10.2 (Janus Kinase 2)
RN  - ISP4442I3Y (baricitinib)
SB  - IM
MH  - Antirheumatic Agents/*administration & dosage/adverse effects/pharmacology
MH  - Arthritis, Rheumatoid/*drug therapy/physiopathology
MH  - Azetidines/*administration & dosage/adverse effects/pharmacology
MH  - Humans
MH  - Janus Kinase 1/antagonists & inhibitors
MH  - Janus Kinase 2/antagonists & inhibitors
MH  - Purines/*administration & dosage/adverse effects/pharmacology
MH  - Pyrazoles/*administration & dosage/adverse effects/pharmacology
MH  - Randomized Controlled Trials as Topic
MH  - Sulfonamides/*administration & dosage/adverse effects/pharmacology
OTO - NOTNLM
OT  - Janus kinase inhibitor
OT  - Rheumatoid arthritis
OT  - baricitinib
OT  - efficacy
OT  - herpes zoster
OT  - safety
EDAT- 2020/03/17 06:00
MHDA- 2021/01/22 06:00
CRDT- 2020/03/17 06:00
PHST- 2020/03/17 06:00 [pubmed]
PHST- 2021/01/22 06:00 [medline]
PHST- 2020/03/17 06:00 [entrez]
AID - 10.1080/14740338.2020.1743263 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2020 May;19(5):545-551. doi: 10.1080/14740338.2020.1743263. 
      Epub 2020 Mar 21.